S1UTRSP5, a short restructured RNA from SLIT1 3'UTR, mitigates mouse cardiac remodeling via enhancing SlRT1 activity.

IF 10.4 1区 医学 Q1 CHEMISTRY, MULTIDISCIPLINARY
Acta Pharmacologica Sinica Pub Date : 2026-09-01 Epub Date: 2026-06-11 DOI:10.1038/s41401-026-01859-w
Jin-Feng Su, Tao Ou, Xiao-Yao Liu, Xue-Min Su, Ya Wang, Yi-Hong Wen, Yuan Gao, Ruo-Han Li, Lu-Fang Huang, Chuan-Meng Zhou, Heng-Li Zhao, Jie-Ning Zhu, Ning Ma, Xi-Long Zheng, Yu-Peng Liu, Jin-Dong Xu, Hui Li, Xian-Hong Fang, Zhi-Xin Shan
{"title":"S1UTRSP5, a short restructured RNA from SLIT1 3'UTR, mitigates mouse cardiac remodeling via enhancing SlRT1 activity.","authors":"Jin-Feng Su, Tao Ou, Xiao-Yao Liu, Xue-Min Su, Ya Wang, Yi-Hong Wen, Yuan Gao, Ruo-Han Li, Lu-Fang Huang, Chuan-Meng Zhou, Heng-Li Zhao, Jie-Ning Zhu, Ning Ma, Xi-Long Zheng, Yu-Peng Liu, Jin-Dong Xu, Hui Li, Xian-Hong Fang, Zhi-Xin Shan","doi":"10.1038/s41401-026-01859-w","DOIUrl":null,"url":null,"abstract":"<p><p>The 3' untranslated regions (3'UTRs) have been known to regulate mRNA location, stability, and translation. 3'UTR length regulation is involved in the pathogenesis of cardiac dysfunction; however, more about the roles of 3'UTRs in cardiac remodeling remains elusive. In this study, we found slit guidance ligand 1 (SLIT1) 3'UTR with 3074 nt in length, which was 10-fold higher than SLIT1 coding sequence (CDS), was significantly decreased in the myocardium of patients with heart failure (HF) (n = 40) in comparison with healthy organ donors (n=17). We revealed that SLIT1 3'UTR and the 1526 nt fragment of SLIT1 3'UTR (FS1UTR) mainly and specifically combined miR-34a-5p, and improved cardiac remodeling through the miR-34a-5p/SIRT1 axis independently of Slit1 expression. Furthermore, a 260 nt restructured RNA derived from FS1UTR, S1UTRSP5, which contains 5 binding sites of miR-34a-5p seed sequence, alleviated cardiac remodeling in vitro and in vivo. We demonstrated that S1UTRSP5 blocked the function of miR-34a-5p and activated the SIRT1-PGC-1α-Nrf2 axis in cardiomyocytes, and promoted the SIRT1/Smad3 signal in cardiac fibroblasts and the SIRT1-eNOS-VEGFA axis in endothelial cells, collectively contributing to the amelioration of cardiac remodeling. These results provide new insights into the development of S1UTRSP5 as a novel inhibitor of miR-34a-5p for cardiac remodeling and HF. The human SLIT1 3'UTR or FS1UTR combines miR-34a-5p to increase SIRT1 level in CMs, CFs and ECs. Notably, S1UTRSP5, a 260-nt stable RNA derived from SLIT1 3'UTR, efficiently sponged miR-34a-5p to activate SIRT1-PGC-1α-Nrf2 pathway in CMs, and to promote SIRT1/Smad3 signal in CFs and the SIRT1-eNOS-VEGFA pathway in ECs, collectively contributing to amelioration of cardiac remodeling.</p>","PeriodicalId":6942,"journal":{"name":"Acta Pharmacologica Sinica","volume":" ","pages":"2525-2538"},"PeriodicalIF":10.4000,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13486678/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Pharmacologica Sinica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41401-026-01859-w","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/6/11 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}
引用次数: 0

Abstract

The 3' untranslated regions (3'UTRs) have been known to regulate mRNA location, stability, and translation. 3'UTR length regulation is involved in the pathogenesis of cardiac dysfunction; however, more about the roles of 3'UTRs in cardiac remodeling remains elusive. In this study, we found slit guidance ligand 1 (SLIT1) 3'UTR with 3074 nt in length, which was 10-fold higher than SLIT1 coding sequence (CDS), was significantly decreased in the myocardium of patients with heart failure (HF) (n = 40) in comparison with healthy organ donors (n=17). We revealed that SLIT1 3'UTR and the 1526 nt fragment of SLIT1 3'UTR (FS1UTR) mainly and specifically combined miR-34a-5p, and improved cardiac remodeling through the miR-34a-5p/SIRT1 axis independently of Slit1 expression. Furthermore, a 260 nt restructured RNA derived from FS1UTR, S1UTRSP5, which contains 5 binding sites of miR-34a-5p seed sequence, alleviated cardiac remodeling in vitro and in vivo. We demonstrated that S1UTRSP5 blocked the function of miR-34a-5p and activated the SIRT1-PGC-1α-Nrf2 axis in cardiomyocytes, and promoted the SIRT1/Smad3 signal in cardiac fibroblasts and the SIRT1-eNOS-VEGFA axis in endothelial cells, collectively contributing to the amelioration of cardiac remodeling. These results provide new insights into the development of S1UTRSP5 as a novel inhibitor of miR-34a-5p for cardiac remodeling and HF. The human SLIT1 3'UTR or FS1UTR combines miR-34a-5p to increase SIRT1 level in CMs, CFs and ECs. Notably, S1UTRSP5, a 260-nt stable RNA derived from SLIT1 3'UTR, efficiently sponged miR-34a-5p to activate SIRT1-PGC-1α-Nrf2 pathway in CMs, and to promote SIRT1/Smad3 signal in CFs and the SIRT1-eNOS-VEGFA pathway in ECs, collectively contributing to amelioration of cardiac remodeling.

S1UTRSP5是一种来自SLIT1 3'UTR的短重组RNA,通过增强SlRT1活性来减轻小鼠心脏重构。
已知3‘非翻译区(3’ utr)调节mRNA的位置、稳定性和翻译。3'UTR长度调节参与心功能障碍的发病机制;然而,关于3'UTRs在心脏重构中的作用仍然是未知的。在本研究中,我们发现心力衰竭(HF)患者(n= 40)心肌中裂隙引导配体1 (SLIT1) 3'UTR长度为3074 nt,是SLIT1编码序列(CDS)的10倍,与健康器官供者(n=17)相比显著降低。我们发现SLIT1 3'UTR和SLIT1 3'UTR的1526 nt片段(FS1UTR)主要和特异性结合miR-34a-5p,并通过独立于SLIT1表达的miR-34a-5p/SIRT1轴改善心脏重构。此外,从FS1UTR, S1UTRSP5衍生的260 nt重组RNA,包含miR-34a-5p种子序列的5个结合位点,在体外和体内减轻了心脏重构。我们证明S1UTRSP5阻断miR-34a-5p的功能,激活心肌细胞中的SIRT1- pfc -1α- nrf2轴,促进心脏成纤维细胞中的SIRT1/Smad3信号和内皮细胞中的SIRT1- enos - vegfa轴,共同促进心脏重塑的改善。这些结果为S1UTRSP5作为miR-34a-5p的新型抑制剂用于心脏重塑和HF的发展提供了新的见解。人类SLIT1 3'UTR或FS1UTR结合miR-34a-5p可提高CMs、cf和ec中的SIRT1水平。值得注意的是,S1UTRSP5是一种来自SLIT1 3'UTR的260 nt稳定RNA,它能有效地吸收miR-34a-5p,激活CMs中的SIRT1- pgc -1α- nrf2通路,促进CFs中的SIRT1/Smad3信号和ECs中的SIRT1- enos - vegfa通路,共同促进心脏重构的改善。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Acta Pharmacologica Sinica
Acta Pharmacologica Sinica 医学-化学综合
CiteScore
15.10
自引率
2.40%
发文量
4365
审稿时长
2 months
期刊介绍: APS (Acta Pharmacologica Sinica) welcomes submissions from diverse areas of pharmacology and the life sciences. While we encourage contributions across a broad spectrum, topics of particular interest include, but are not limited to: anticancer pharmacology, cardiovascular and pulmonary pharmacology, clinical pharmacology, drug discovery, gastrointestinal and hepatic pharmacology, genitourinary, renal, and endocrine pharmacology, immunopharmacology and inflammation, molecular and cellular pharmacology, neuropharmacology, pharmaceutics, and pharmacokinetics. Join us in sharing your research and insights in pharmacology and the life sciences.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书